Biopharma industry pushes back on FDA's 'America First' user fee proposals
生物医药行业反对美国食品药品监督管理局的“美国优先”用户费用提案

Biopharma industry representatives are taking issue with some of the FDA’s more political proposals in the next round of user fee agreements, particularly ones that would limit the small business waiver to only US applicants and reduce user fees for companies that run their Phase 1 trials in the US.
生物医药行业代表对美国食品药品监督管理局(FDA)在下一轮用户付费协议中的一些更具政治色彩的提案提出异议，尤其是那些将小企业减免限定为仅适用于美国申请者，以及为在美国开展一期临床试验的公司降低用户费用的提议。